February 23, 2015
Otsuka Pharmaceutical and UCB Japan said on February 20 that their antiepilepsy agent E Keppra (levetiracetam) was approved for use as a monotherapy for partial-onset seizures, including secondary generalized seizures. The drug has been only used as an adjunctive therapy...read more